$74,926.39 ownership Payment -- Pfizer Inc to Dr. Richard Brown

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

This report analyzes a significant payment of $74,926.39 made by Pfizer Inc. to Dr. Richard Brown, an Internal Medicine physician in Jersey City, NJ, on July 26, 2025. The payment type is categorized as 'ownership,' indicating Dr. Brown holds an ownership or investment interest in a company or product related to Pfizer, specifically linked to the drug Imbruvica. This is a substantial amount for an ownership interest, especially when compared to typical payments for consulting or speaking engagements, though ownership stakes can vary widely in value. Potential conflict of interest considerations are important here. When a physician has a financial stake, such as ownership, in a drug or the company that manufactures it, it raises questions about whether their prescribing decisions could be influenced by their personal financial gain. While the Sunshine Act requires disclosure to promote transparency, it doesn't inherently mean a conflict exists or that care is compromised. However, it does warrant careful consideration by patients. Comparing this to industry averages is complex for ownership interests, as their value fluctuates. However, for a single disclosed ownership interest of this magnitude, it is likely higher than the average payment received by many physicians in Internal Medicine, who more commonly receive smaller payments for consulting, meals, or speaker fees. The vast majority of physicians do not have significant ownership stakes in pharmaceutical companies. For patients, understanding this relationship is crucial. It means Dr. Brown has a direct financial interest in the success of Imbruvica or a related entity. While this doesn't automatically mean his recommendations are biased, it's a factor to be aware of. Patients should feel empowered to discuss any financial relationships their doctor has with pharmaceutical companies, especially when significant ownership is involved, to ensure their treatment plans are based solely on their best medical interests.

Patient Guidance: What This Payment Means for You

It's understandable to have questions when you see a payment like this. This $74,926.39 payment to Dr. Brown from Pfizer, related to Imbruvica, is an 'ownership' interest. This means Dr. Brown has a financial stake in the company or product. While this doesn't automatically mean your care will be affected, it's a good reason to be informed. At your next appointment, you can ask Dr. Brown directly: 'I saw on the Open Payments database that you have an ownership interest related to Imbruvica. Can you tell me more about that relationship and how it might relate to my treatment decisions?' This opens a dialogue. Remember, many physician-pharma relationships are routine and disclosed for transparency. However, significant ownership stakes, like this one, warrant more attention. It's about ensuring your treatment plan is always based on what's best for your health, not influenced by financial ties. If you have persistent concerns after discussing it with your doctor, you can always seek a second opinion.

Payment Context: Is This Amount Normal?

Payments to physicians in Internal Medicine vary widely, but a disclosed ownership interest of nearly $75,000 is substantial and likely higher than the average payment received by physicians in this specialty, who more commonly receive smaller amounts for consulting or speaking. While many Internal Medicine physicians may receive some form of payment or transfer of value, a significant ownership stake is less common than other types of payments.

Regulatory Context: Sunshine Act Requirements

The Sunshine Act, part of the Affordable Care Act, mandates that pharmaceutical companies and medical device manufacturers report payments and other transfers of value made to physicians and teaching hospitals. Ownership interests, like the one reported here, are subject to these reporting requirements if they meet certain thresholds. This type of disclosure aims to increase transparency and allow patients and the public to understand potential financial relationships.

Related Topics

This payment is related to the following healthcare transparency topics:

• pharma-payments
• internal-medicine
• ownership-interest
• sunshine-act
• imbruvica
• conflict-of-interest
• pfizer

Understanding ownership Payments

Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.

Frequently Asked Questions About This Payment

Does my doctor take pharma money?

You can check if your doctor receives payments from pharmaceutical or medical device companies through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. This database publicly lists reported transfers of value. Seeing payments doesn't automatically mean your doctor is acting improperly; many payments are for legitimate purposes like research or education. However, it's important information for understanding potential influences on prescribing habits and ensuring transparency in your healthcare.

Should I worry about this payment?

This specific payment of $74,926.39 represents an ownership interest, meaning Dr. Brown has a financial stake in a company or product related to Imbruvica. While this is a significant amount and warrants awareness, it doesn't automatically mean your care is compromised. It's a signal to be informed and to discuss any concerns openly with your doctor. Consider it a piece of information to help you have a more informed conversation about your treatment.

What types of pharma payments are most concerning?

Payments that can raise more concern are often those that directly influence prescribing, such as large consulting fees, speaker fees for promotional events, or significant ownership stakes in drug manufacturers. While meals and travel can also be influential, direct financial interests like ownership or substantial consulting arrangements are generally viewed with more scrutiny due to their potential to create a direct financial incentive for prescribing specific products.

How do I talk to my doctor about pharma relationships?

Start by stating what you've observed: 'I saw on the Open Payments database that you received a payment from [Company Name] for [Payment Type].' Then, ask open-ended questions like: 'Can you explain this relationship?' or 'How does this relationship influence your prescribing decisions?' or 'Does this relate to the medications you prescribe for me?' Be calm and curious, aiming for understanding rather than accusation. A good doctor will be open to discussing these relationships.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for doctors to accept payments from pharmaceutical and medical device companies, provided these relationships are disclosed under the Sunshine Act. The Act requires companies to report payments made to physicians, promoting transparency. Doctors can receive payments for various reasons, including research, speaking engagements, consulting, and ownership interests. The legality hinges on proper disclosure and adherence to regulations designed to prevent kickbacks and undue influence.

Does pharma money affect what my doctor prescribes?

Research suggests that financial relationships between doctors and pharmaceutical companies can influence prescribing patterns. Even small payments or gifts can subtly shape preferences. This doesn't mean doctors are intentionally prescribing inappropriately, but financial ties can create unconscious biases. Transparency through the Open Payments database allows patients to be aware of these relationships and discuss them with their doctors to ensure treatment decisions are solely based on patient needs.

How does this compare to other doctors in this specialty?

For Internal Medicine physicians, payments can range from small amounts for meals to substantial fees for consulting or research. An ownership interest of nearly $75,000 is likely higher than the average payment received by many doctors in this field, as ownership stakes are less common than other forms of compensation. While many physicians may have some disclosed relationship, a significant financial stake like this stands out and suggests a deeper financial connection to the industry.

Related Reports

• View Dr. Richard Brown's full payment report
• Pfizer Inc full spending report
• Browse all Internal Medicine payments
• Browse all payments in New Jersey
• Search for other payments